Inicio > Oncología > Tratamiento con interferón alfa-2B recombinante en el carcinoma basocelular > Página 8

Tratamiento con interferón alfa-2B recombinante en el carcinoma basocelular

  • criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45(2):228-47.
  • Nova-Villanueva J, Sánchez-Vanegas G, Porras de Quintana L. Cáncer de piel: Perfil epidemiológico de un centro de referencia en colombia 2003-2005. Revista de Salud Pública. 2007;9:595-601.
  • Viñas García M, Algozaín Acosta Y, Álvarez Campos L, Quintana Díaz JC. Comportamiento del carcinoma basocelular facial en artemisa durante la última década. Revista Cubana de Estomatología. 2011;48:121-8.
  • Salazar J, Romero Z, Romero N, Payares Y, Castillo Y, Mavárez C. Frecuencia de neoplasias malignas en piel. Multiciencias. 2010;10(3):287-93.
  • Lukaszuk BLM, Cidral Muniz E, Leite da Veiga M, Iribas JL. Aspectos epidemiológicos del cáncer no melanoma de piel en un servicio de dermatología de la ciudad de santa fe – argentina 2007. Revista argentina de dermatología. 2008;89:30-6.
  • Stollery N. Skin conditions affecting the elderly. Practitioner. 2013 Mar;257(1759):30-1.
  • Stolle LB, Kjerkegaard UK. A single center retrospective study on 959 excisions of non-melanoma skin cancer in 2011. J Plast Reconstr Aesthet Surg. [Letter]. 2013 Nov;66(11):1630-2.
  • Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. J Med Econ. [Research Support, Non-U.S. Gov’t]. 2013;16(6):777-83.
  • Kricker A, Armstrong B, Hansen V, Watson A, Singh-Khaira G, Lecathelinais C, et al. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients. J Am Acad Dermatol. 2014 Mar;70(3):456-64.
  • Surdu S, Fitzgerald EF, Bloom MS, Boscoe FP, Carpenter DO, Haase RF, et al. Occupational exposure to ultraviolet radiation and risk of non-melanoma skin cancer in a multinational european study. PLoS One. 2013;8(4):e62359.
  • Radiotis G, Roberts N, Czajkowska Z, Khanna M, Korner A. Nonmelanoma skin cancer: Disease-specific quality-of-life concerns and distress. Oncol Nurs Forum. 2014 Ene 1;41(1):57-65.
  • Epstein EH, Jr. Skin cancer: Basal cell carcinoma–pay your money, take your choice. Nat Rev Clin Oncol. 2013 Sep;10(9):489-90.
  • Bulman A, Neagu M, Constantin C. Immunomics in skin cancer – improvement in diagnosis, prognosis and therapy monitoring. Curr Proteomics. 2013 Sep;10(3):202-17.
  • Khalesi M, Whiteman DC, Tran B, Kimlin MG, Olsen CM, Neale RE. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol. [Meta-Analisis]. 2013 Oct;37(5):534-43.
  • Jurciukonyte R, Vincerzevskiene I, Krilaviciute A, Bylaite M, Smailyte G. Epidemiology of basal cell carcinoma in lithuania, 1996-2010. Br J Dermatol. 2013 Nov;169(5):1100-5.
  • Graves M, Sheehan DJ, Lesher JL, Jr. Skin retraction as a marker for aggressive basal cell carcinoma. Dermatol Surg. [Case ReportsLetter]. 2013 Dic;39(12):1943-4.
  • Bordianu A, Florescu IP, Muresan A, Bernad E, Craina M, Sargan I. Anatomo-clinical aspects of the basal cell carcinoma at the level of the cephalic end. Rom J Morphol Embryol. 2013;54(3):609-12.
  • Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. Basal cell carcinoma: A paradigm for targeted therapies. Expert Opin Pharmacother. [Review]. 2013 Jul;14(10):1307-18.
  • Basset-Seguin N, Bissonnette R, Girard C, Haedersdal M, Lear JT, Paul C, et al. Consensus recommendations for the treatment of basal cell carcinomas in gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol. 2013 Abr 13.
  • Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clinical Cancer Research. 2011;17(10):3378-87.
  • Ferreira FR, Pevide Bda C, Rodrigues RF, Nascimento LF, Lira ML. Differences in age and topographic distribution of the different histological subtypes of basal cell carcinoma, taubate (sp), brazil. An Bras Dermatol. 2013 Sep-Oct;88(5):726-30.
  • Moredo Romo E, Moreira Preciado M, Pérez López A. Uso de los interferones en dermatología: Experiencia con el alfa-interferón en la micosis fungoide. Revista Cubana de Farmacia. 2004;38(2):1-3.
  • Leis-Dosil VM, Prats-Caelles I, Rubio-Flores C. Interferon eyedrops in the treatment of basal cell carcinoma of the eyelid. Actas Dermosifiliogr. [Letter]. 2013 Abr 19.
  • Leis-Dosil VM, Prats-Caelles I, Rubio-Flores C. Interferon eyedrops in the treatment of basal cell carcinoma of the eyelid. Actas Dermosifiliogr. [Letter]. 2014 Feb 25.
  • Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: Efficacy and cost comparisons. Dermatol Surg. 2013 Sep;39(9):1306-16.
  • Graells J, Ojeda RM, Garcia-Cruz A. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma. Actas Dermosifiliogr. 2014 January – February;105(1):53-9.
  • Turan A, Saricaoglu H, Baskan EB, Toker SC, Tunali S. Treatment of infiltrating basal cell carcinoma with the combination of intralesional ifnalpha-2b and topical imiquimod 5% cream. Int J Dermatol. 2009 Feb;48(2):214-5.
  • Barcelona-Perez S, López-Saura P, Bello-Rivero I. Tratamiento de carcinomas basocelulares y espinocelulares avanzados, recurrentes y resistentes a tratamientos previos con una formulación de ifns con propiedades sinérgicas. Estudio prospectivo y abierto. 2012 [citado 2014 Feb 15]: Disponible en:

http://files.sld.cu/boletincnscs/files/2011/03/respubblono-1-2011yanelda.pdf.